Evidence map›Paper›PMID 38700782›Full record

ArticleInternal and emergency medicine2024

Association between serum levels of GDF-15, suPAR, PIVKA-II, sdLDL and clinical outcomes in hospitalized COVID-19 patients.

Alessio Molfino, Emanuela Anastasi, Eleonora Assanto, Ludovica Toccini, Giovanni Imbimbo, Antonietta Gigante, Valentina Viggiani, Antonella Farina, Orietta Picconi, Antonio Angeloni and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal and emergency medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alessio MolfinoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. alessio.molfino@uniroma1.it.ORCID 0000-0002-6432-0236
Emanuela AnastasiDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy. emanuela.anastasi@uniroma1.it.
Eleonora AssantoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Ludovica TocciniDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Giovanni ImbimboDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Antonietta GiganteDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Valentina ViggianiDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Antonella FarinaDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Orietta PicconiNational HIV/AIDS Center, Istituto Superiore Di Sanità, Rome, Italy.
Antonio AngeloniDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Maurizio MuscaritoliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

Funding

Sapienza Università di Roma 000051-2021
6 · The paper itself

Abstract

To quantify the circulating levels of novel serum biomarkers including GDF-15, PIVKA-II, sdLDL, suPAR, and of CRP in hospitalized COVID-19 patients compared with healthy subjects, and to evaluate their association(s) with outcomes in COVID-19. We considered patients with confirmed COVID-19, hospitalized in an Internal Medicine ward. The clinical characteristics were collected, including the number and type of comorbidities. Serum levels of GDF-15, PIVKA-II, suPAR, sdLDL, as well as CRP were measured. As outcomes, we considered Intensive Care Unit (ICU) transfer or death, as well as the length of stay (days) and in-hospital complications. Data were statistically analyzed, as appropriate, and a p value < 0.05 was considered significant. Ninety-three patients and 20 healthy controls were enrolled. COVID-19 patients vs. controls showed higher median levels of GDF-15 (p < 0.0001), PIVKA-II (p < 0.0001) and sdLDL (p = 0.0002), whereas no difference was observed for suPAR. In COVID-19 patients, the most frequent comorbidities were arterial hypertension (62.4%) and cardiovascular disease (30.1%). GDF-15 levels positively correlated with age (r = 0.433, p < 0.0001), and this correlation was confirmed for suPAR (r = 0.308, p = 0.003) and CRP (Rho = 0.40 p < 0.0001), but not for PIVKA-II and sdLDL. Higher GDF-15 levels were associated with a higher number of comorbidities (p = 0.021). The median length of stay was 22 (15; 30) days. During hospitalization, 15 patients (16%) were ICU transferred, and 6 (6.45%) died. GDF-15 serum levels correlated with the length of stay (rho = 0.27 p = 0.010), and were associated with ICU transfer or death (p = 0.003), as well as PIVKA-II (p = 0.038) and CRP (p < 0.001). Moreover, higher GDF-15 and PIVKA-II serum levels were associated with infectious complications (p = 0.008 and p = 0.017, respectively). In this cohort of hospitalized COVID-19 patients, novel inflammatory biomarkers, including GDF-15, suPAR and PIVKA II were associated with some patient's clinical characteristics, complications, and poor outcomes.

Indexed as

BiomarkersCOVID-19Growth Differentiation Factor 15AgedCholesterol, LDLC-Reactive ProteinFemaleHospitalizationHumansLength of StayMaleMiddle AgedProtein PrecursorsReceptors, Urokinase Plasminogen ActivatorBiomarkersCholesterol, LDLC-Reactive ProteinGDF15 protein, humanGrowth Differentiation Factor 15PLAUR protein, humanProtein PrecursorsReceptors, Urokinase Plasminogen ActivatorBiomarkersCOVID-19GDF-15InflammationInternal medicinePIVKA-IIPrognosissdLDLsuPAR

Identifiers

PMID38700782
PMCPMC11405538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.